Gilead Sciences stock gains on HIV licensing push and solid dividend

Published on 09/19/2026 at 11:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock closed at USD 150.11 on Nasdaq on September 18, 2026, up more than 22 percent since the start of the year. The company expects its HIV drug lenacapavir to generate about USD 1 billion in 2026 sales, supporting higher HIV growth guidance.

Photorealistischer Biotech-Campus von Gilead Sciences mit Glaslabor und Wissenschaftlern — Gilead Sciences Forschungscampus mit ISIN US3755581036 modernes Biopharma-Labor Kalifornien Glasfassade Wissenschaftler arbeiten, Illustration mit AI erstellt.

Gilead Sciences, Inc. stock (ISIN US3755581036) traded at USD 150.11 on Nasdaq at the close on September 18, 2026, marking a gain of just over 22 percent since the start of 2026 and underscoring renewed investor confidence in the biopharmaceutical group.

HIV licensing deals strengthen growth outlook

As Yahoo Finance reported on September 18, 2026, Gilead Sciences has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean.

According to Yahoo Finance, Gilead expects lenacapavir to generate about USD 1 billion in sales in 2026, providing a significant new revenue stream in its HIV franchise compared with earlier years when the product was not yet widely commercialized.

The same report notes that Gilead has raised its expected 2026 HIV-product sales growth to 9 percent to 10 percent, up from a previously lower range, reflecting the anticipated contribution from lenacapavir under expanded access agreements.Yahoo Finance

Beyond the PAHO agreement, regional partners are also involved in voluntary licensing arrangements for once-yearly HIV prevention treatments based on Gilead's lenacapavir, which broadens the geographic scope of the company’s HIV portfolio.Ground News

Dividend and recent performance support Gilead Sciences stock

Per data summarized by MarketBeat, Gilead Sciences stock was trading at USD 122.74 on January 1, 2026, and has since risen to around USD 150.11, an increase of approximately 22 percent year-to-date as of September 18, 2026.

The same overview indicates that Gilead shares closed at USD 150.11 on Nasdaq at 4:00 p.m. Eastern Time on September 18, 2026, with a modest daily decline of 0.52 percent from the previous close, illustrating that the broader upward trend has recently been accompanied by small short-term fluctuations.MarketBeat

According to MarketBeat on September 19, 2026, the consensus rating on Gilead Sciences stock stands at Moderate Buy, with an average analyst price target of USD 158.78, implying upside potential of about 5.8 percent from the USD 150.11 closing level.

For income-oriented investors, Gilead offers a quarterly dividend that, on an annualized basis, corresponds to a yield of roughly 2.2 percent at recent share prices, based on a total annual payout of USD 3.28 per share cited in current analyst summaries.MarketBeat

The combination of year-to-date price appreciation of more than 22 percent, an estimated dividend yield above 2 percent and positive HIV franchise momentum places Gilead Sciences stock in a comparatively attractive position among large-cap biopharmaceutical names focused on antiviral therapies.MarketBeat

Risk factors and upcoming catalysts

One key risk for Gilead is the concentration of its growth expectations in the HIV segment, where regulatory decisions, competitive developments and real-world uptake of lenacapavir-based products could cause actual sales to deviate from the roughly USD 1 billion 2026 target.Yahoo Finance

Additionally, expanded voluntary licensing arrangements, while supportive of broader access, may influence pricing and margin dynamics over time, requiring Gilead to balance volume growth with profitability as agreements with partners and organizations such as PAHO scale up.Ground News

Looking ahead, investors will monitor the next set of quarterly results and updated guidance from Gilead Sciences to see whether rising HIV-product sales and the lenacapavir ramp materialize in line with the 9 percent to 10 percent growth outlook for 2026 HIV revenues and whether the broader antiviral portfolio adds incremental support to earnings.

Gilead Sciences stock price snapshot

Gilead Sciences stock closed at USD 150.11 on Nasdaq on September 18, 2026, in United States dollars, with this price serving as the current reference level for investors evaluating the company’s valuation relative to the consensus analyst target of USD 158.78.